202 related articles for article (PubMed ID: 22844580)
1. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.
Antoon JW; Lai R; Struckhoff AP; Nitschke AM; Elliott S; Martin EC; Rhodes LV; Yoon NS; Salvo VA; Shan B; Beckman BS; Nephew KP; Burow ME
Sci Rep; 2012; 2():539. PubMed ID: 22844580
[TBL] [Abstract][Full Text] [Related]
2. The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.
Kastrati I; Joosten SEP; Semina SE; Alejo LH; Brovkovych SD; Stender JD; Horlings HM; Kok M; Alarid ET; Greene GL; Linn SC; Zwart W; Frasor J
Mol Cancer Res; 2020 Jul; 18(7):1018-1027. PubMed ID: 32245803
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition.
Antoon JW; Nitzchke AM; Martin EC; Rhodes LV; Nam S; Wadsworth S; Salvo VA; Elliott S; Collins-Burow B; Nephew KP; Burow ME
Int J Oncol; 2013 Apr; 42(4):1139-50. PubMed ID: 23403951
[TBL] [Abstract][Full Text] [Related]
4. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH
Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589
[TBL] [Abstract][Full Text] [Related]
5. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.
D'Assoro AB; Liu T; Quatraro C; Amato A; Opyrchal M; Leontovich A; Ikeda Y; Ohmine S; Lingle W; Suman V; Ecsedy J; Iankov I; Di Leonardo A; Ayers-Inglers J; Degnim A; Billadeau D; McCubrey J; Ingle J; Salisbury JL; Galanis E
Oncogene; 2014 Jan; 33(5):599-610. PubMed ID: 23334326
[TBL] [Abstract][Full Text] [Related]
6. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
7. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K
Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
[TBL] [Abstract][Full Text] [Related]
8. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
9. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
Zhou C; Nitschke AM; Xiong W; Zhang Q; Tang Y; Bloch M; Elliott S; Zhu Y; Bazzone L; Yu D; Weldon CB; Schiff R; McLachlan JA; Beckman BS; Wiese TE; Nephew KP; Shan B; Burow ME; Wang G
Breast Cancer Res; 2008; 10(6):R105. PubMed ID: 19087274
[TBL] [Abstract][Full Text] [Related]
11. Tumor Necrosis Factor (TNF)-α-Induced Protein 8-like-2 (TIPE2) Inhibits Proliferation and Tumorigenesis in Breast Cancer Cells.
Wang K; Ren Y; Liu Y; Zhang J; He JJ
Oncol Res; 2017 Jan; 25(1):55-63. PubMed ID: 28081733
[TBL] [Abstract][Full Text] [Related]
12. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
13. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
15. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells.
Ahmad A; Sarkar SH; Bitar B; Ali S; Aboukameel A; Sethi S; Li Y; Bao B; Kong D; Banerjee S; Padhye SB; Sarkar FH
Mol Cancer Ther; 2012 Oct; 11(10):2193-201. PubMed ID: 22821148
[TBL] [Abstract][Full Text] [Related]
16. The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-κB signaling.
Wei W; Liu W; Cassol CA; Zheng W; Asa SL; Ezzat S
Mol Cell Biol; 2012 Nov; 32(22):4662-73. PubMed ID: 22988296
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
18. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.
Huber MA; Azoitei N; Baumann B; Grünert S; Sommer A; Pehamberger H; Kraut N; Beug H; Wirth T
J Clin Invest; 2004 Aug; 114(4):569-81. PubMed ID: 15314694
[TBL] [Abstract][Full Text] [Related]
19. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1.
Li CW; Xia W; Huo L; Lim SO; Wu Y; Hsu JL; Chao CH; Yamaguchi H; Yang NK; Ding Q; Wang Y; Lai YJ; LaBaff AM; Wu TJ; Lin BR; Yang MH; Hortobagyi GN; Hung MC
Cancer Res; 2012 Mar; 72(5):1290-300. PubMed ID: 22253230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
